Clinical and genetic features of CMT2T in Italian patients confirm the importance of MME pathogenic variants in idiopathic, late-onset axonal neuropathies.
CMT
MME
genotype–phenotype correlation
late‐onset peripheral neuropathies
neprilysin
Journal
Journal of the peripheral nervous system : JPNS
ISSN: 1529-8027
Titre abrégé: J Peripher Nerv Syst
Pays: United States
ID NLM: 9704532
Informations de publication
Date de publication:
09 Sep 2024
09 Sep 2024
Historique:
revised:
19
08
2024
received:
22
05
2024
accepted:
22
08
2024
medline:
10
9
2024
pubmed:
10
9
2024
entrez:
9
9
2024
Statut:
aheadofprint
Résumé
Since 2016, biallelic mutations in the membrane metalloendopeptidase (MME) gene have been associated with late-onset recessive CMT2 (CMT2T). More recently, heterozygous mutations have also been identified in familial and sporadic patients with late-onset axonal neuropathy, ranging from subclinical to severe. This indicates that the heterozygous MME variants may not be fully penetrant, or alternatively, that they may be a potential risk factor for neuropathy. Here, we describe the clinical, neurophysiological, and genetic findings of 32 CM2T Italian patients. The patients were recruited from four different Italian referral centers. Following a comprehensive battery of neurological, electrophysiological, and laboratory examinations, the patients' DNA was subjected to sequencing in order to identify any variants in the gene. Bioinformatic and modeling analyses were performed to evaluate the identified variants' effects. We observe a relatively mild axonal sensory-motor neuropathy with a greater impairment of the lower extremities. Biallelic and monoallelic patients exhibit comparable disease severity, with an earlier onset observed in those with biallelic variants. When considering a subgroup with more than 10 years of disease, it becomes evident that biallelic patients exhibit a more severe form of neuropathy. This suggests that they are more prone to quick progression. CM2T has been definitively defined as a late-onset neuropathy, with a typical onset in the fifth to sixth decades of life and a more rapidly progressing worsening for biallelic patients. CMT2T can be included in the neuropathies of the elderly, particularly if MME variants heterozygous patients are included.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Since 2016, biallelic mutations in the membrane metalloendopeptidase (MME) gene have been associated with late-onset recessive CMT2 (CMT2T). More recently, heterozygous mutations have also been identified in familial and sporadic patients with late-onset axonal neuropathy, ranging from subclinical to severe. This indicates that the heterozygous MME variants may not be fully penetrant, or alternatively, that they may be a potential risk factor for neuropathy. Here, we describe the clinical, neurophysiological, and genetic findings of 32 CM2T Italian patients.
METHODS
METHODS
The patients were recruited from four different Italian referral centers. Following a comprehensive battery of neurological, electrophysiological, and laboratory examinations, the patients' DNA was subjected to sequencing in order to identify any variants in the gene. Bioinformatic and modeling analyses were performed to evaluate the identified variants' effects.
RESULTS
RESULTS
We observe a relatively mild axonal sensory-motor neuropathy with a greater impairment of the lower extremities. Biallelic and monoallelic patients exhibit comparable disease severity, with an earlier onset observed in those with biallelic variants. When considering a subgroup with more than 10 years of disease, it becomes evident that biallelic patients exhibit a more severe form of neuropathy. This suggests that they are more prone to quick progression.
INTERPRETATION
CONCLUSIONS
CM2T has been definitively defined as a late-onset neuropathy, with a typical onset in the fifth to sixth decades of life and a more rapidly progressing worsening for biallelic patients. CMT2T can be included in the neuropathies of the elderly, particularly if MME variants heterozygous patients are included.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Journal of the Peripheral Nervous System published by Wiley Periodicals LLC on behalf of Peripheral Nerve Society.
Références
Azzedine H, Senderek J, Rivolta C, Chrast R. Molecular genetics of Charcot‐Marie‐Tooth disease: from genes to genomes. Mol Syndromol. 2012;3(5):204‐214. doi:10.1159/000343487
Bird TD. Charcot‐Marie‐Tooth hereditary neuropathy overview. September 28, 1998 [updated March 14, 2024]. In: Adam MP, Feldman J, Mirzaa GM, et al., eds. GeneReviews®. University of Washington, Seattle; 1993 –2024.
Berciano J, García A, Gallardo E, et al. Intermediate Charcot‐Marie‐Tooth disease: an electrophysiological reappraisal and systematic review. J Neurol. 2017;264(8):1655‐1677.
Higuchi Y, Takashima H. Clinical genetics of Charcot‐Marie‐Tooth disease. J Hum Genet. 2023;68(3):199‐214. doi:10.1038/s10038‐022‐01031‐2
Higuchi Y, Hashiguchi A, Yuan J, et al. Mutations in MME cause an autosomal‐recessive Charcot‐Marie‐Tooth disease type 2. Ann Neurol. 2016;79(4):659‐672. doi:10.1002/ana.24612
Lupo V, Frasquet M, Sánchez‐Monteagudo A, et al. Characterising the phenotype and mode of inheritance of patients with inherited peripheral neuropathies carrying MME mutations. J Med Genet. 2018;55(12):814‐823. doi:10.1136/jmedgenet‐2018‐105650
Yoshimura A, Yuan JH, Hashiguchi A, et al. Genetic profile and onset features of 1005 patients with Charcot‐Marie‐Tooth disease in Japan. J Neurol Neurosurg Psychiatry. 2019;90(2):195‐202. doi:10.1136/jnnp‐2018‐318839
Auer‐Grumbach M, Toegel S, Schabhüttl M, et al. Rare variants in MME, encoding metalloprotease neprilysin, are linked to late‐onset autosomal‐dominant axonal polyneuropathies. Am J Hum Genet. 2016;99(3):607‐623. doi:10.1016/j.ajhg.2016.07.008
Senderek J, Lassuthova P, Kabzińska D, et al. The genetic landscape of axonal neuropathies in the middle‐aged and elderly: focus on MME. Neurology. 2020;95(24):e3163‐e3179. doi:10.1212/WNL.0000000000011132
Cadoni A, Mancardi GL, Zaccheo D, et al. Expression of common acute lymphoblastic leukemia antigen (CD 10) by myelinated fibers of the peripheral nervous system. J Neuroimmunol. 1993;45(1–2):61‐66. doi:10.1016/0165‐5728(93)90164‐t
Turner AJ, Tanzawa K. Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX. FASEB J. 1997;11(5):355‐364. doi:10.1096/fasebj.11.5.9141502
Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405‐424. doi:10.1038/gim.2015.30
Baux D, Van Goethem C, Ardouin O, et al. MobiDetails: Online DNA variants interpretation. Eur J Hum Genet. 2021;29(2):356‐360. doi:10.1038/s41431‐020‐00755‐z
Cortese A, Tozza S, Yau WY, et al. Cerebellar ataxia, neuropathy, vestibular areflexia syndrome due to RFC1 repeat expansion. Brain. 2020;143(2):480‐490. doi:10.1093/brain/awz418
Depondt C, Donatello S, Rai M, et al. MME mutation in dominant spinocerebellar ataxia with neuropathy (SCA43). Neurol Genet. 2016;2(5):e94. doi:10.1212/NXG.0000000000000094